News headlines about ArQule (NASDAQ:ARQL) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ArQule earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.24083489059 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

ArQule (NASDAQ:ARQL) traded up 3.6239% during mid-day trading on Friday, reaching $1.1295. The company had a trading volume of 49,338 shares. ArQule has a 1-year low of $0.92 and a 1-year high of $1.82. The firm has a 50-day moving average of $1.13 and a 200 day moving average of $1.15. The company’s market capitalization is $80.39 million.

ArQule (NASDAQ:ARQL) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. During the same period in the previous year, the firm posted ($0.07) EPS. On average, analysts predict that ArQule will post ($0.43) earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded ArQule from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact ArQule (ARQL) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Insider Buying and Selling by Quarter for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.